844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      Overview

      We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
      NK (Common Stock) $3.15 - 0.25 (7.35%)
      Data provided by Nasdaq. Minimum 15 minutes delayed.

      Latest News

      NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

      Apr 04, 2017 | Press Releases

      by Jen Hodson | Apr 4, 2017 | Press Releases |

      Read More

      NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma

      Mar 20, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:N

      Read More

      NantKwest to Present at Upcoming Investor Conferences

      Mar 06, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) toda

      Read More

      Upcoming Events
      There are currently no events scheduled.
      Receive E-mail Alerts
      Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.